Scientific and medical news

Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation

31.07.20151752

As non-valvular atrial fibrillation (AF) brings a risk of stroke, oral anticoagulants (OAC) are recommended.

Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death

30.07.20151745

Mitral valve prolapse (MVP) may present with ventricular arrhythmias and sudden cardiac death (SCD) even in the absence of hemodynamic impairment.

Association of prior beta-blocker use and the outcomes of patients with out-of-hospital cardiac arrest

29.07.20151552

Beta-blocker therapy is one of the most commonly prescribed treatments for patients with cardiac conditions. In patients with out-of-hospital cardiac arrest (OHCA) however, recent data suggest prior treatment with beta-blockers could be harmful by lowering the incidence of a shockable presenting rhythm.

Anticoagulation advisable during pregnancy with Fontan circulation

27.07.20151825

Women with Fontan circulation can successfully complete pregnancy, but an increase in cardiac and neonatal morbidity exists, results by French researchers published in the International Journal of Cardiology show.

FDA approves alirocumab for lowering of LDL in certain patients

24.07.20151633

The FDA and Sanofi/Regeneron announced that the agency has approved alirocumab, a PCSK9 inhibitor, for lowering of LDL in addition to diet and maximally tolerated statin therapy in patients with heterozygous familial hypercholesterolemia or those with clinical atherosclerotic CVD.

Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: a FIELD substudy

23.07.20151468

Dislipidemia in type 2 diabetes mellitus contributes to arterial endothelial dysfunction and an increased risk of cardiovascular disease.

Amgen has announced that it has received marketing authorization from the European Commission for evolocumab, a PCSK9 inhibitor

22.07.20151640

The drug, to be marketed as Repatha (Amgen), is the first PCSK9 inhibitor to be approved for intensive reduction of LDL, according to a company press release.